EKSO

Ekso Bionics Holdings, Inc. [EKSO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EKSO Stock Summary

Top EKSO Correlated Resources

EKSO


Top 10 Correlated ETFs

EKSO


Top 10 Correlated Stocks

EKSO


In the News

11:25 07 Dec 2022 EKSO

Ekso Bionics Holdings, Inc. (EKSO) Q3 2022 Earnings Call Transcript

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Matt Steinberg - Investor Relations Steven Sherman - Chairman and Chief Executive Officer Scott Davis - President and Chief Operating Officer Jerome Wong - Chief Financial Officer Operator Greetings and welcome to Ekso Bionics Third Quarter 2022 Financial Results Call. [Operator Instructions] As a reminder, this conference is being recorded.

07:35 07 Dec 2022 EKSO

Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -37.50% and 7.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

04:05 07 Dec 2022 EKSO

Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference

SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that Scott Davis, President and Chief Operating Officer, will be presenting virtually at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.

04:34 07 Dec 2022 EKSO

Ekso Bionics: Fragile Opportunity

Ekso Bionics has added a new use case for the EksoNR exoskeleton, multiple sclerosis, opening some new avenues for marginal revenue growth. Pre-Covid, Ekso had started to see sharp improvements in operating margins, but that trend came to a clear stop over the last two years.

07:53 07 Dec 2022 EKSO

Ekso Bionics Holdings, Inc. (EKSO) CEO Steven Sherman on Q2 2022 Results - Earnings Call Transcript

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2022 Results Conference Call July 28, 2022 4:30 PM ET Company Participants David Carey - Head, Investor Relations Steven Sherman - Chairman & CEO Scott Davis - President & Chief Operating Officer Jerome Wong - interim Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Kyle Bauser - LakeStreet Capital Operator Hello, and welcome to the Ekso Bionics Q2 2022 Financial Results Conference Call.

06:44 07 Dec 2022 EKSO

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

08:00 07 Dec 2022 EKSO

Ekso Bionics to Report Second Quarter 2022 Financial Results on July 28

RICHMOND, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2022 after the close of trading on Thursday, July 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

06:48 07 Dec 2022 EKSO

Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of 12.20% and 19.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

08:03 07 Dec 2022 EKSO

Ekso Bionics to Report First Quarter 2022 Financial Results on April 28

RICHMOND, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2022 after the close of trading on Thursday, April 28, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.

11:06 07 Dec 2022 EKSO

Ekso Bionics Holdings, Inc. (EKSO) CEO Steven Sherman on Q4 2021 Results - Earnings Call Transcript

Ekso Bionics Holdings, Inc. (EKSO) CEO Steven Sherman on Q4 2021 Results - Earnings Call Transcript

EKSO Financial details

Company Rating
Neutral
Market Cap
16.03M
Income
-14.77M
Revenue
13.44M
Book val./share
2.19
Cash/share
2.23
Dividend
-
Dividend %
-
Employees
55
Optionable
No
Shortable
Yes
Earnings
22 Feb 2023
P/E
-1.44
Forward P/E
-0.82
PEG
0.3
P/S
1.29
P/B
0.61
P/C
0.58
P/FCF
-1.22
Quick Ratio
4.15
Current Ratio
4.68
Debt / Equity
0.04
LT Debt / Equity
0.04
-
-
EPS (TTM)
-1.15
EPS next Y
-1.57
EPS next Q
-0.3
EPS this Y
-63.8%
EPS next Y
36.52%
EPS next 5Y
36.52%
EPS last 5Y
-42.11%
Revenue last 5Y
8.87%
Revenue Q/Q
-3.92%
EPS Q/Q
43.48%
-
-
-
-
SMA20
-50%
SMA50
-50%
SMA100
-50%
Inst Own
12.98%
Inst Trans
0.39%
ROA
-38%
ROE
-45%
ROC
-0.5%
Gross Margin
52%
Oper. Margin
-117%
Profit Margin
-110%
Payout
-
Shs Outstand
13.14M
Shs Float
12.24M
-
-
-
-
Target Price
9
52W Range
1.03-3.49
52W High
-57%
52W Low
+29%
RSI
50
Rel Volume
0.89
Avg Volume
34.31K
Volume
30.5K
Perf Week
19.44%
Perf Month
-5.84%
Perf Quarter
-28.33%
Perf Half Y
-32.46%
-
-
-
-
Beta
1.84294
-
-
Volatility
0.09%, 0.16%
Prev Close
-3.01%
Price
1.29
Change
-2.27%

EKSO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
3.12.782.91.240.92
Net income per share
-12.27-6.61-2.53-2.21-0.8
Operating cash flow per share
-13.15-5.43-3.29-1.22-0.91
Free cash flow per share
-13.35-5.46-3.3-1.22-0.92
Cash per share
11.721.882.271.83.31
Book value per share
9.010.671.420.623.05
Tangible book value per share
8.720.621.380.623.05
Share holders equity per share
9.010.671.420.623.05
Interest debt per share
3.221.380.740.560.19
Market cap
55.19M107.15M28.05M62.76M27.92M
Enterprise value
34.38M104.51M20.35M53.75M-10.26M
P/E ratio
-1.9-3.97-2.31-3.97-2.86
Price to sales ratio
7.519.462.027.072.48
POCF ratio
-1.77-4.83-1.78-7.17-2.5
PFCF ratio
-1.74-4.81-1.77-7.17-2.49
P/B Ratio
2.5839.284.1314.150.75
PTB ratio
2.5839.284.1314.150.75
EV to sales
4.689.221.466.05-0.91
Enterprise value over EBITDA
-1.29-4.2-1.84-3.571.13
EV to operating cash flow
-1.1-4.72-1.29-6.140.92
EV to free cash flow
-1.09-4.69-1.29-6.140.92
Earnings yield
-0.53-0.25-0.43-0.25-0.35
Free cash flow yield
-0.57-0.21-0.56-0.14-0.4
Debt to equity
0.230.970.060.750.05
Debt to assets
0.440.850.690.780.24
Net debt to EBITDA
0.780.110.70.64.2
Current ratio
3.811.482.43.76.97
Interest coverage
-48.78-45.05-43.33-95.62-122.37
Income quality
1.070.821.30.551.14
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.461.030.530.870.94
Research and developement to revenue
1.290.520.330.280.24
Intangibles to total assets
0.020.010.0100
Capex to operating cash flow
0.010.01000.01
Capex to revenue
-0.06-0.0100-0.01
Capex to depreciation
-0.26-0.09-0.090-0.11
Stock based compensation to revenue
0.330.250.160.290.22
Graham number
49.879.978.985.557.42
ROIC
-1.1-3.59-1.18-0.85-0.33
Return on tangible assets
-0.78-1.55-0.56-0.77-0.2
Graham Net
6.23-0.70.190.032.71
Working capital
25.77M4.84M10.98M13.45M40.94M
Tangible asset value
20.71M2.54M6.61M00
Net current asset value
18.34M40K3.69M2.26M35.85M
Invested capital
0.331.840.470.870.06
Average receivables
3.07M3.52M4.3M3.39M4.03M
Average payables
1.96M2.33M1.7M1.5M2.3M
Average inventory
2.5M2.67M2.23M1.98M2.11M
Days sales outstanding
137.01117.89136.59139.27151.31
Days payables outstanding
167.17164.0297.11143.72252.18
Days of inventory on hand
208.96175.2127.01189.39181.97
Receivables turnover
2.663.12.672.622.41
Payables turnover
2.182.233.762.541.45
Inventory turnover
1.752.082.871.932.01
ROE
-1.36-9.89-1.78-3.57-0.26
Capex per share
-0.19-0.03-0.0100

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.240.320.20.270.25
Net income per share
-0.15-0.23-0.36-0.23-0.33
Operating cash flow per share
-0.2-0.24-0.33-0.33-0.2
Free cash flow per share
-0.2-0.24-0.33-0.33-0.21
Cash per share
3.433.192.852.482.23
Book value per share
3.092.942.642.462.19
Tangible book value per share
3.092.942.642.462.19
Share holders equity per share
3.092.942.642.462.19
Interest debt per share
0.190.180.170.170.26
Market cap
58.49M33.6M36.64M21.26M20.39M
Enterprise value
17.42M-4.59M2.55M-8.49M-5.38M
P/E ratio
-7.47-2.93-1.98-1.78-1.18
Price to sales ratio
19.188.2414.276.146.13
POCF ratio
-23.63-10.93-8.71-5-7.87
PFCF ratio
-23.07-10.93-8.71-5-7.47
P/B Ratio
1.50.91.090.670.71
PTB ratio
1.50.91.090.670.71
EV to sales
5.71-1.131-2.45-1.62
Enterprise value over EBITDA
-9.811.7-0.573.241.55
EV to operating cash flow
-7.041.49-0.6122.08
EV to free cash flow
-6.871.49-0.6121.97
Earnings yield
-0.03-0.09-0.13-0.14-0.21
Free cash flow yield
-0.04-0.09-0.11-0.2-0.13
Debt to equity
0.050.050.060.070.04
Debt to assets
0.230.240.240.220.27
Net debt to EBITDA
23.1314.167.6411.367.41
Current ratio
10.56.977.228.164.68
Interest coverage
-116.21-126.44-156.93-111.34-107.47
Income quality
1.261.070.911.430.6
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.751.011.10.610.8
Research and developement to revenue
0.20.20.390.270.28
Intangibles to total assets
00000
Capex to operating cash flow
000-0.040
Capex to revenue
0000.050
Capex to depreciation
0000.530
Stock based compensation to revenue
0.230.20.220.180.17
Graham number
3.283.864.653.584.03
ROIC
-0.06-0.11-0.11-0.09-0.12
Return on tangible assets
-0.04-0.06-0.1-0.07-0.11
Graham Net
2.762.612.312.121.74
Working capital
44.42M40.94M37.15M34.5M28.9M
Tangible asset value
00000
Net current asset value
37.43M35.85M32.37M30.53M26.06M
Invested capital
0.060.060.060.070.12
Average receivables
3.23M4M3.34M3.34M3.37M
Average payables
1.68M2.58M2.49M2.05M2.22M
Average inventory
2.51M2.76M3.02M3.27M3.39M
Days sales outstanding
92.13102.94117.3186.7891.87
Days payables outstanding
94.78168.35194.78100.9130.75
Days of inventory on hand
126.88121.48183.71161.55192.16
Receivables turnover
0.980.870.771.040.98
Payables turnover
0.950.530.460.890.69
Inventory turnover
0.710.740.490.560.47
ROE
-0.05-0.08-0.14-0.09-0.15
Capex per share
0000.010

EKSO Frequently Asked Questions

What is Ekso Bionics Holdings, Inc. stock symbol ?

Ekso Bionics Holdings, Inc. is a US stock , located in Richmond california of California and trading under the symbol EKSO

What is Ekso Bionics Holdings, Inc. stock quote today ?

Ekso Bionics Holdings, Inc. stock price is $1.29 today.

Is Ekso Bionics Holdings, Inc. stock public?

Yes, Ekso Bionics Holdings, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap